Precision BioSciences Reports Board & Executive Changes
Ticker: DTIL · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1357874
| Field | Detail |
|---|---|
| Company | Precision Biosciences Inc (DTIL) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.000005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: PBIO
TL;DR
PBIO filed an 8-K: new directors elected, exec comp updated, shareholder votes and financials disclosed.
AI Summary
On June 4, 2024, Precision BioSciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers. It also covers the submission of matters to a vote of security holders and financial statement disclosures.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future financial performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Precision BioSciences, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but specific names and details of the changes are not provided in the excerpt.
Were there any significant changes to executive compensation arrangements?
Yes, the filing mentions updates to 'Compensatory Arrangements of Certain Officers', though specific details are not in the provided text.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the excerpt.
Are there any new financial statements or exhibits being filed?
Yes, the filing includes 'Financial Statements and Exhibits'.
What is the primary business of Precision BioSciences, Inc.?
Precision BioSciences, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Filing Stats: 886 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-06-10 08:00:10
Key Financial Figures
- $0.000005 — ch registered Common stock, par value $0.000005 per share DTIL The Nasdaq Capital M
Filing Documents
- dtil-20240604.htm (8-K) — 93KB
- dtil-ex10_1.htm (EX-10.1) — 172KB
- 0000950170-24-071082.txt ( ) — 416KB
- dtil-20240604.xsd (EX-101.SCH) — 28KB
- dtil-20240604_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. At the Meeting, a total of 5,219,553 shares of the Company's common stock, par value $0.000005 (the "Common Stock"), were present in person or represented by proxy, representing approximately 75% of the Common Stock outstanding as of the April 8, 2024 record date. The following are the voting results for the proposals considered and voted upon at the Meeting, each of which were described in the Company's Proxy Statement. Item 1 – Election of two Class II directors to serve until the Company's annual meeting of stockholders to be held in 2027 and until their respective successors have been duly elected and qualified. Votes FOR Votes WITHHELD Broker Non-Votes Stanley R. Frankel, M.D. 3,011,614 430,720 1,777,219 Samuel Wadsworth, Ph.D. 3,013,365 428,969 1,777,219 Item 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 5,162,463 46,031 11,059 0
– Approval of the amendment and restatement of the 2019 Plan
Item 3 – Approval of the amendment and restatement of the 2019 Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 2,597,767 836,298 8,269 1,777,219 Item 4 – Approval of the adjournment of the Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Meeting to approve Item 3. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 2,649,161 786,749 6,424 1,777,219 Based on the foregoing votes, Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. were elected as Class II directors, and Item 2, Item 3, and Item 4 were approved.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Precision BioSciences, Inc. 2019 Incentive Award Plan, as Amended and Restated. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: June 10, 2024 By: /s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer